AFM24 is a bispecific EGFR/CD16A innate cell engager antibody that has shown preclinical activity in controlling tumor growth in in vitro and mouse models of EGFR-positive tumors, independently from the presence of EGFR mutation (140). Here, EGFR is linked to neoplasm.